GSK plc (NYSE:GSK) today reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
Telsey Advisory Group Downgrades Vintage Wine Estates to Underperform, Lowers Price Target to $1.5
Telsey Advisory Group analyst Joseph Feldman downgrades Vintage Wine Estates (NASDAQ:VWE) from Market Perform to Underperform and lowers the price target from $3.5 to $1.5.
